Cyclacel announces multiple abstracts selected for presentation at American Association for Cancer Research Annual Meeting

- Translational studies highlight unique mechanism of action and new potential clinical applications for sapacitabine and seliciclib -

BERKELEY HEIGHTS, NJ - April 1, 2010 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) today announced that six abstracts highlighting translational and preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for presentation at the American Association of Cancer Research (AACR) Annual Meeting, being held from April 17-21, 2010, in Washington, DC.

The abstracts can be accessed through the AACR website, www.aacr.org. Abstract titles are provided below. Please note that according to AACR policy, all data are embargoed until the time of the beginning of the presentation.

Sapacitabine:

"Understanding the pathways involved in the repair of CNDAC induced DNA damage"
Date/Time: Tuesday, Apr 20, 2010, 9:00 - 12:00 EDT
Abstract Number: 3502

Seliciclib and Second Generation CDK Inhibitors:

"Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer"
Date/Time: Sunday, Apr 18, 2010, 14:25 – 14:40 EDT
Abstract Number: 22

"Therapeutic potential of CDK inhibitors in MLL leukemias"
Date/Time: Tuesday, Apr 20, 2010, 14:00 – 17:00 EDT
Abstract Number: 3886

"A novel derivative of the CDK inhibitor roscovitine that induces apoptosis in CLL and overcomes stromal cell-mediated protection"
Date/Time: Tuesday, Apr 20, 2010, 14:00 – 17:00 EDT
Abstract Number: 4431

CYC116:

"Tumor cell resistance mechanisms to aurora kinase inhibitors"
Date/Time: Sunday, Apr 18, 2010, 14:00 – 17:00 EDT
Abstract Number: 633

Plk1 Inhibitors:

"Discovery, biological characterization and oral antitumor activity of polo-like kinase 1 (Plk1) selective small molecule inhibitors"
Date/Time: Tuesday, Apr 20, 2010, 14:00 - 17:00 EDT
Abstract Number: 4435

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 3 development for the treatment of acute myeloid leukemia in the elderly under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration, and in Phase 2 studies for myelodysplastic syndromes and lung cancer. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and

Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact for Cyclacel Pharmaceuticals, Inc.

Investors/Media:
Corey Sohmer,
(908) 517-7330
csohmer@cyclacel.com